Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis


Autoria(s): Melo, L. M.; Perosso, J.; Almeida, B. F. M.; Silva, K. L. O.; Somenzari, M. A.; Lima, Valéria Marçal Felix de
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

03/12/2014

03/12/2014

01/02/2014

Resumo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Processo FAPESP: 09/50426-9

Processo FAPESP: 10/13166-6

Leishmania (L.) chagasi is the etiologic agent of visceral leishmaniasis (VL) that can be transmitted to humans and dogs. VL in Brazil represents a serious public health problem; therefore, it is important to study new alternatives to treat infected dogs. In dogs, the therapeutic arsenal against canine VL is limited. The immunomodulator protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride (P-MAPA) improves immunocompetence when the immune system is impaired, but its dependence on Toll-like receptors (TLRs) and the mechanisms involved in immune response remain unclear. The in vitro action of P-MAPA on the expression of TLR2 and TLR4, reactive oxygen species (ROS), nitric oxide (NO) and p38 mitogen-activated protein kinase (p38 MAPK) and IKK phosphorylation was studied in mononuclear cells from peripheral blood and macrophages from healthy and Leishmania-infected dogs. The PBMC or macrophages were isolated and cultured with different concentrations of P-MAPA (20,100 and 200 mu g/ml) in a humid environment at 37 degrees C with 5% CO2. Observation revealed that Leishmania-infected dogs showed a decrease in TLR2 in macrophages compared with healthy dogs and in induction with P-MAPA. ROS were increased in PBMCs from Leishmania spp.-infected dogs compared with healthy dogs and P-MAPA improved ROS production. NO production was increased in culture supernatant from macrophages stimulated by P-MAPA in both healthy and Leishmania spp. infected dogs. Treatment of macrophages from healthy dogs with immunomodulatory P-MAPA induced p38 MAPK and IKK phosphorylation, suggesting signal transduction by this pathway. These findings suggest that P-MAPA has potential as a therapeutic drug in the treatment of canine visceral leishmaniasis. (C) 2014 Elsevier B.V. All rights reserved.

Formato

373-378

Identificador

http://dx.doi.org/10.1016/j.intimp.2013.12.012

International Immunopharmacology. Amsterdam: Elsevier Science Bv, v. 18, n. 2, p. 373-378, 2014.

1567-5769

http://hdl.handle.net/11449/112406

10.1016/j.intimp.2013.12.012

WOS:000331412900023

Idioma(s)

eng

Publicador

Elsevier B.V.

Relação

International Immunopharmacology

Direitos

closedAccess

Palavras-Chave #Leishmania sp. #P-MAPA #Dog #Immunomodulatory #TLR
Tipo

info:eu-repo/semantics/article